Vancouver, British Columbia--(Newsfile Corp. - February 17, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that the first patients of 2026 have been treated using the Company's MDMA capsules at authorised clinics across Australia, operating under the Authorised Prescriber Scheme.

The Company continues to supply its finished MDMA drug product directly to authorised clinics under Australia's regulated prescribing framework, supporting ongoing patient treatment programs across the country. According to aggregated information obtained through a Freedom of Information request to the Therapeutic Goods Administration (TGA), publicly reported data from Australia's Authorised Prescriber Scheme indicated that no serious adverse events (SAEs) were recorded among patients receiving MDMA-assisted therapy under the Scheme as of September 16, 2025.

More recently, the Australian Department of Veterans' Affairs (DVA) recently announced a $740 million veterans rehabilitation plan that includes support for psychedelic-assisted therapy for eligible veterans with PTSD.

"Entering 2026 with active treatments underway across a growing clinic network is an important step in the continued development of regulated MDMA-assisted therapy," said Dane Stevens, CEO and Co-Founder of Optimi Health. "Our direct-to-clinic supply model allows us to maintain manufacturing oversight, ensure our product is cost effective, and support authorised prescribers within Australia's established regulatory framework. We believe this structure provides a scalable pathway for responsible commercial expansion."

Patient-Reported Outcomes (PROs) are being collected by the Australian National University (ANU) as part of an expanding real-world evidence (RWE) program focused on MDMA-assisted therapy for the treatment of Post-Traumatic Stress Disorder (PTSD).

Optimi holds a Drug Establishment Licence issued by Health Canada that authorises the manufacture of 60 mg and 40 mg MDMA capsules for regulated therapeutic use, including the treatment of Post-Traumatic Stress Disorder, where permitted by local regulatory frameworks.

According to the Australian Bureau of Statistics, approximately 5-6% of Australians experience PTSD in a given year, representing roughly 1.3 to 1.5 million people, with higher prevalence among veterans and first responders.

Clinicians, hospital networks, and authorised programs operating under the Authorised Prescriber Scheme may seek information regarding access through Mind Medicine Australia at ilan@mindmedicineaustralia.org.

For global enquiries outside of Australia, please contact sales@optimihealth.ca.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10615/283872_e9a6112204b1bb34_001full.jpg

About Optimi Health Corp.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) is a leading producer of prescribed psychedelic treatments for mental health therapies. As a Health Canada-licensed, GMP compliant pharmaceutical manufacturer producing validated MDMA and botanical psilocybin products from two 10,000-square-foot facilities in British Columbia, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia via the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, please visit www.optimihealth.ca.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements"), including with respect to the role of psychedelic medicines in insured mental health care. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.com. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283872